Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Epidemiology and costs of chronic kidney disease in North Carolina.

Vupputuri S.

N C Med J. 2008 May-Jun;69(3):205-7. No abstract available.

PMID:
18751353
2.

Editorial comment.

El Nahas M.

Nephron Clin Pract. 2009;113(4):c293. No abstract available.

PMID:
19950440
3.

The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination.

Menon V, Sarnak MJ.

Am J Kidney Dis. 2005 Jan;45(1):223-32. No abstract available.

PMID:
15696466
4.

Community Care of North Carolina and the medical home approach to chronic kidney disease.

DuBard CA, Cockerham J.

N C Med J. 2008 May-Jun;69(3):229-32. No abstract available.

PMID:
18751361
5.

The drug add-on component--have all provider types seen budget neutrality?

Mentz K.

Nephrol News Issues. 2005 Sep;19(10):42-4. Review. No abstract available.

PMID:
16187646
6.

Policy forum: chronic kidney disease in North Carolina.

Ricketts TC 3rd, Hastings J.

N C Med J. 2008 May-Jun;69(3):196. No abstract available.

PMID:
18751351
7.

Chronic kidney disease in North Carolina.

Alexander-Bratcher K, Plescia M, Skipper L, Silberman P, Holmes M.

N C Med J. 2008 May-Jun;69(3):197-204. No abstract available.

PMID:
18751352
8.

Selected data on chronic kidney disease in North Carolina.

Buescher PA.

N C Med J. 2008 May-Jun;69(3):243-6. No abstract available.

PMID:
18751365
9.

Costs and financing of kidney transplantation in the United States.

Mendez R, Aswad S, Dessouki A, Cicciarelli J, Mendez RG.

Transplant Proc. 1992 Oct;24(5):2127-8. No abstract available.

PMID:
1413009
10.

Regarding: "Management of glomerular proteinuria: a commentary".

Brenner BM.

J Am Soc Nephrol. 2004 May;15(5):1354-5; discussion 1356-7. Review. No abstract available.

11.

Preventing renal disease progression: can complete renin-angiotensin-aldosterone blockade work?

Schreiber MJ Jr.

Cleve Clin J Med. 2008 Oct;75(10):699-700, 703-4. No abstract available.

PMID:
18939385
12.

Epidemiology and prevention.

Levy E.

Curr Opin Nephrol Hypertens. 1998 May;7(3):251-2. No abstract available.

PMID:
9617553
13.

Medicare coverage of angiotensin-converting enzyme inhibitors.

Velakaturi VN.

Ann Intern Med. 2005 Dec 20;143(12):918; author reply 918. No abstract available.

PMID:
16365479
14.

Pediatric chronic kidney disease in North Carolina.

Ferris M, Patel UD, Massengill S, Gipson D, Conley W, Layton JB, Nagaraj S, Primack W.

N C Med J. 2008 May-Jun;69(3):208-14. No abstract available.

15.

Drugs take the spotlight in steering clinical, economic direction for ESRD.

Neumann ME.

Nephrol News Issues. 2004 Jun;18(7):50-1. No abstract available.

PMID:
15232997
16.

Renin-angiotensin system inhibitors in proteinuric chronic kidney disease.

Hirsch S.

Compr Ther. 2009 Summer;35(2):91-5. Review.

PMID:
19618757
17.

Genetics and kidney disease. Duke Med Scholars Program.

Krentz JF.

N C Med J. 2008 May-Jun;69(3):247. No abstract available.

PMID:
18751366
18.

Vasopeptidase inhibition.

Burnett JC.

Curr Opin Nephrol Hypertens. 2000 Sep;9(5):465-8. Review. No abstract available.

PMID:
10990362
19.

Public health initiatives to prevent and detect chronic kidney disease in North Carolina.

Pullen-Smith B, Plescia M.

N C Med J. 2008 May-Jun;69(3):224-6. No abstract available.

PMID:
18751358
20.

Chasing the (MCP) codes.

Amerling R.

Nephrol News Issues. 2004 May;18(6):34. No abstract available.

PMID:
15160417
Items per page

Supplemental Content

Support Center